Pomalidomide-C3-NH2 hydrochloride
97%
- Product Code: 56131
CAS:
2154342-45-5
| Molecular Weight: | 366.80 g./mol | Molecular Formula: | C₁₆H₁₉ClN₄O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD31729296 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, dry, sealed |
Product Description:
Pomalidomide-C3-NH2 hydrochloride is primarily used in the field of pharmaceutical research, particularly in the development of targeted cancer therapies. It serves as a key intermediate in the synthesis of pomalidomide derivatives, which are known for their immunomodulatory and anti-angiogenic properties. These derivatives are often explored for their potential in treating multiple myeloma and other hematologic malignancies. Additionally, its modified structure allows for enhanced binding to cereblon, a protein involved in the ubiquitination process, making it valuable in the study of protein degradation pathways. Researchers also utilize this compound to investigate its efficacy in combination therapies, aiming to improve treatment outcomes for patients with refractory or relapsed cancers.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.250 | 10-20 days | $2,025.20 |
+
-
|
Pomalidomide-C3-NH2 hydrochloride
Pomalidomide-C3-NH2 hydrochloride is primarily used in the field of pharmaceutical research, particularly in the development of targeted cancer therapies. It serves as a key intermediate in the synthesis of pomalidomide derivatives, which are known for their immunomodulatory and anti-angiogenic properties. These derivatives are often explored for their potential in treating multiple myeloma and other hematologic malignancies. Additionally, its modified structure allows for enhanced binding to cereblon, a protein involved in the ubiquitination process, making it valuable in the study of protein degradation pathways. Researchers also utilize this compound to investigate its efficacy in combination therapies, aiming to improve treatment outcomes for patients with refractory or relapsed cancers.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :